loading page

On the role of antibody affinity in the IgE mediated allergic response
  • +5
  • Sviatlana Starchenka,
  • Martin Bachmann,
  • Pascal S. Krenger,
  • Mona Mohsen,
  • Matthias Kramer,
  • Piers Whitehead,
  • Monique Vogel,
  • Matthew Heath
Sviatlana Starchenka
Allergy Therapeutics Plc
Author Profile
Martin Bachmann
University Clinic for Rheumatology and Immunology Inselhospital

Corresponding Author:[email protected]

Author Profile
Pascal S. Krenger
University Clinic for Rheumatology and Immunology Inselhospital
Author Profile
Mona Mohsen
University Clinic for Rheumatology and Immunology Inselhospital
Author Profile
Matthias Kramer
Allergy Therapeutics Plc
Author Profile
Piers Whitehead
SeromYx Systems
Author Profile
Monique Vogel
University Clinic for Rheumatology and Immunology Inselhospital
Author Profile
Matthew Heath
Allergy Therapeutics Plc
Author Profile

Abstract

Type I hypersensitivity, also known as classical allergy, is mediated via allergen-specific IgE antibodies bound to type I FcR (FcεRI) on the surface of mast cells and basophils upon cross-linking by allergens. This IgE-mediated cellular activation may be blocked by allergen-specific IgG through multiple mechanisms, including direct neutralization of the allergen or engagement of the inhibitory receptor FcγRIIb which blocks IgE signal transduction. In addition, co-engagement of FcεRI and FcγRIIb by IgE-IgG-allergen immune-complexes causes down-regulation of receptor bound IgE, resulting in desensitization of the cells. Both, activation of FcεRI by allergen-specific IgE and engagement of FcγRIIb by allergen-specific IgG are driven by allergen-binding. Here we delineate the distinct roles of antibody affinity versus avidity in driving these processes and discuss the role of IgG subclasses in inhibiting basophil and mast cell activation.
27 Feb 2024Submitted to Allergy
27 Feb 2024Submission Checks Completed
27 Feb 2024Assigned to Editor
27 Feb 2024Review(s) Completed, Editorial Evaluation Pending
17 Mar 2024Editorial Decision: Revise Minor
23 Jun 20241st Revision Received
25 Jun 2024Review(s) Completed, Editorial Evaluation Pending
25 Jun 2024Submission Checks Completed
25 Jun 2024Assigned to Editor
28 Jun 2024Reviewer(s) Assigned
06 Jul 2024Editorial Decision: Revise Minor
08 Jul 20242nd Revision Received
11 Jul 2024Assigned to Editor
11 Jul 2024Submission Checks Completed
11 Jul 2024Review(s) Completed, Editorial Evaluation Pending
11 Jul 2024Editorial Decision: Accept